A study evaluating the impact of immunosuppressive therapies on the immunogenicity and efficacy of SARS-CoV-2 vaccination in patients with autoimmune glomerular and rheumatic diseases treated with rituximab or other non-biological immunosuppressive therapies
Latest Information Update: 12 Aug 2021
At a glance
- Drugs AZD 1222 (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- 12 Aug 2021 New trial record
- 06 Aug 2021 Results published in the Annals of the Rheumatic Diseases